Establishment Labs Holdings Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter Caldini
- Full Time Employees
- 1,004
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 11401 century oaks terrace Austin TX United States 78758
- IPO Date
- Jul 19, 2018
- CIK
- 0001688757
- Website
- establishmentlabs.com
- Similar Companies
- Business
- Establishment Labs Holdings Inc. is a Costa Rica-based global medical technology company specializing in women's health, primarily focused on aesthetic and reconstructive plastic surgery. The company designs, develops, manufactures, and markets a comprehensive portfolio of silicone-filled breast and body shaping implants, marketed under the Motiva Implants brand. Its core products include Motiva silicone gel-filled breast implants featuring proprietary SmoothSilk surface technology, BluSeal barrier layer, and Q Inside Safety Technology with RFID capabilities, as well as Divina breast implants geared towards breast reconstruction, supported by the Divina 3D Simulation System. The company also offers breast tissue expanders, including the Motiva Flora tissue expander with an integrated MRI-conditional port. Additionally, Establishment Labs provides surgical planning software (MotivaImagine) for 3D visualization and customization of breast surgery outcomes and the Puregraft fat grafting system for aesthetic and reconstructive procedures. The company operates a vertically integrated business model with research and development, manufacturing facilities compliant with ISO13485:2016 and FDA standards in Costa Rica, and sales operations spanning over 80 countries including Europe, the Middle East, Africa, Latin America, Asia-Pacific, and North America. Recent major developments include the launch of Motiva Implants in the United States following FDA approval, the company's strategic expansion into minimally invasive breast aesthetics with innovations such as Mia Femtech™, and important operational shifts including a 28% reduction in global headcount aimed at cost control and operational efficiency. Establishment Labs reported a revenue increase exceeding 30% in recent years, achieving approximately $190 million in 2024 and guiding towards $205-$210 million in 2025 with improving EBITDA and positive cash flow expectations. The company continues investing heavily in research and development, holding over 200 patent applications across 25 patent families, and collaborates strategically with plastic surgeons and clinics worldwide to enhance market reach and product adoption. Founded in 2004 and headquartered in Alajuela, Costa Rica, Establishment Labs serves physicians, hospitals, and clinics through a combination of direct sales forces and distributor networks. Its product suite targets women seeking breast augmentation, reconstruction, and body contouring, positioning the company as a prominent innovator and competitor in the global breast aesthetics and reconstruction medical device market.
Company News
Baron Discovery Fund Q3 2026 Portfolio Activity
Establishment Labs Holdings Inc. (ESTA) Q3 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue Estimates
What Establishment Labs (ESTA) Said on Its Q3 Earnings Call
Establishment Labs® Reports Third Quarter 2026 Financial Results
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?
Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
Contrasting Establishment Labs (NASDAQ:ESTA) & OraSure Technologies (NASDAQ:OSUR)
Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of “Moderate Buy” from Brokerages
Establishment Labs: Procedure Economics Strengthens The Bull Case
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of “Moderate Buy” from Brokerages
Deutsche Bank AG Buys New Holdings in Establishment Labs Holdings Inc. $ESTA
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs Q2 Earnings Call Highlights
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs® Reports Second Quarter 2026 Financial Results
Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6